Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Key Documents

View All Documentation

Y0001533

Praziquantel for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonim(y):

Praziquantel, 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór empiryczny (zapis Hilla):
C19H24N2O2
Numer CAS:
55268-74-1
Masa cząsteczkowa:
312.41
Beilstein:
761557
Numer MDL:
MFCD00058531
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
329831478
NACRES:
NA.24

klasa czystości

pharmaceutical primary standard

rodzina API

praziquantel

producent / nazwa handlowa

EDQM

Zastosowanie

pharmaceutical (small molecule)

format

neat

temp. przechowywania

2-8°C

ciąg SMILES

O=C1CN(CC2N1CCc3ccccc23)C(=O)C4CCCCC4

InChI

1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2

Klucz InChI

FSVJFNAIGNNGKK-UHFFFAOYSA-N

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Zastosowanie

Praziquantel for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Opakowanie

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Inne uwagi

Sales restrictions may apply.
This page may contain text that has been machine translated.

produkt powiązany

Numer produktu
Opis
Cennik

P2670000

Praziquantel, European Pharmacopoeia (EP) Reference Standard

PHR1391

Praziquantel, Pharmaceutical Secondary Standard; Certified Reference Material

1554658

Praziquantel Related Compound A, United States Pharmacopeia (USP) Reference Standard

1554603

Praziquantel, United States Pharmacopeia (USP) Reference Standard

1554669

Praziquantel Related Compound B, United States Pharmacopeia (USP) Reference Standard

1554670

Praziquantel Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR2961

Praziquantel Related Compound A, pharmaceutical secondary standard, certified reference material

PHR2962

Praziquantel Related Compound B, pharmaceutical secondary standard, certified reference material

PHR2963

Praziquantel Related Compound C, pharmaceutical secondary standard, certified reference material

Zwroty wskazujące rodzaj zagrożenia

H412

Zwroty wskazujące środki ostrożności

P273

Klasyfikacja zagrożeń

Aquatic Chronic 3

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 1

Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Przepraszamy, ale COA dla tego produktu nie jest aktualnie dostępny online.

Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Michael C Jeziorski et al.
International journal for parasitology, 36(6), 625-632 (2006-03-21)
Voltage-gated calcium (Ca2+) channels provide the pathway for Ca2+ influxes that underlie Ca2+ -dependent responses in muscles, nerves and other excitable cells. They are also targets of a wide variety of drugs and toxins. Ca2+ channels are multisubunit protein complexes
Charles H King et al.
PLoS neglected tropical diseases, 5(9), e1321-e1321 (2011-09-29)
Controversy persists about the optimal approach to drug-based control of schistosomiasis in high-risk communities. In a systematic review of published studies, we examined evidence for incremental benefits from repeated praziquantel dosing, given 2 to 8 weeks after an initial dose
J M Bygott et al.
Acta tropica, 111(2), 95-101 (2009-04-21)
The role of praziquantel in hydatid disease has not been well defined. This review evaluates the evidence on the use of praziquantel in treatment of cystic hydatid disease from in vitro and in vivo animal studies, human clinical studies and
Michael J Doenhoff et al.
Current opinion in infectious diseases, 21(6), 659-667 (2008-11-04)
Praziquantel (PZQ) is the only drug being used to treat human schistosomiasis on a large scale. This review focuses on current knowledge about the mechanisms of action of PZQ, prospects for PZQ resistance, possible future alternative drugs and on exhortations
Rong Liu et al.
Parasites & vectors, 4, 201-201 (2011-10-19)
Praziquantel has been used as first-line drug for chemotherapy of schistosomiasis since 1984. Besides praziquantel, artemether and artesunate have also been used for the control of this infectious disease since late 1990s. In this article, we conducted a systematic review
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej